Deep-learning screening identifies covalent SARS-CoV-2 main-protease inhibitor scaffolds
A two-stage deep-learning screen selected cysteine-directed compounds for testing against SARS-CoV-2 3CL protease. Of 32 top-ranked compounds experimentally assayed, 12 inhibited the enzyme; six had IC₅₀ values below 12 μM, with the strongest reported at 1.4 μM. Five of those six exhibited time-dependent inhibition consistent with covalent binding.
Technology: Deep-learning COVCL and NOVCL classifiers integrating a directed message-passing neural network and feed-forward network
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: A two-stage deep-learning screen selected cysteine-directed compounds for testing against SARS-CoV-2 3CL protease.
- Still unknown: Evidence in the primary abstract is biochemical enzyme inhibition and inhibition-mechanism assays. It does not establish antiviral efficacy in cells/animals or clinical benefit. Potency values are for the reported enzyme assay; most tested compounds were inactive, and the six sub-12 μM hits are early leads.
- AI role: The COVCL model first prioritized cysteine-targeted covalent candidates, then NOVCL ranked those candidates for predicted 3CL-protease inhibition. Researchers tested 32 selected molecules in enzyme assays and performed follow-up tests of time-dependent inhibition for active hits.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/36209629/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 86 of works of the same type, year and subfield (OpenAlex work metrics, 25 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.